Do Allergy Shots Cause Inflammation? Local, Regional and Systemic

No — inflammation from allergy shots is not bad; it is the intended mechanism. Allergy shots work specifically by inducing controlled immune inflammation that activates the cellular machinery of immune tolerance. Without sufficient immune activation at the injection site, the dendritic cells and T cells that drive the Th2-to-Treg shift would not receive the stimulation needed to reprogram allergen-specific immune responses. Akdis and Akdis document in the World Allergy Organization Journal that successful allergen immunotherapy requires robust allergen-specific immune activation. The key word is controlled — the goal is enough inflammation to stimulate tolerance without crossing into pathological systemic reaction. As treatment progresses and tolerance develops, inflammation per dose naturally decreases.

Normal injection-site inflammation after allergy shots presents as a wheal-and-flare reaction at the injection point: a raised, pale center (wheal) surrounded by redness extending a few centimeters outward. This is followed by more diffuse swelling, warmth, and itching that typically peaks 15–30 minutes after injection and begins resolving within a few hours. Late-phase local reactions can produce a second wave of swelling and induration 6–12 hours later. Reactions under approximately 5 cm (golf-ball size) are considered within normal range. The reaction may be slightly more pronounced at higher doses during build-up. Consistent moderate reactions are a reassuring sign that the immune system is engaging with each dose.

No — allergy shots do not cause chronic inflammation. The inflammatory responses to each injection are acute and self-resolving, not cumulative in a pathological sense. Systemic inflammatory markers like CRP and IL-6 may transiently elevate after injection but normalize between sessions. Over the course of successful immunotherapy, anti-inflammatory mediators — IL-10, TGF-beta — progressively increase, and the net inflammatory response per allergen dose actually decreases over time. The treatment trajectory is from more inflammation (early build-up) to less inflammation (established maintenance), as immune tolerance reduces the magnitude of the immune response to each allergen challenge. Chronic inflammation is not a documented outcome of SCIT.

Injection-site swelling from allergy shots typically appears within minutes, peaks at 15–30 minutes, and begins resolving within 2–4 hours for the immediate-phase reaction. A secondary late-phase reaction may occur 6–12 hours after injection, producing a second episode of swelling and induration that can last 12–24 hours. Most injection-site reactions fully resolve within 24 hours. Swelling persisting beyond 24 hours is considered a large local reaction and should be reported to your allergist, who may evaluate whether dose adjustment is appropriate. Applying ice immediately after injection can reduce the peak size of both immediate and late-phase local reactions.

Standard over-the-counter anti-inflammatory medications — including ibuprofen (NSAIDs) and acetaminophen — do not meaningfully impair immunotherapy efficacy when used as needed for post-injection symptoms. Short-term NSAID use does not significantly affect the T cell reprogramming or IgG4 production that drives long-term tolerance development. Non-sedating antihistamines, sometimes used as pre-medication before injections, similarly do not interfere with immunotherapy efficacy and are routinely used in clinical practice. Systemic corticosteroids (prednisone, methylprednisolone), used long-term, could theoretically suppress the immune activation needed for tolerance induction — but short courses for unrelated conditions during immunotherapy are generally acceptable. Discuss any new medications with your allergist.